TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05093257

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory investigations for control
Description: 1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory investigations for patients
Description: 1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. Anti-nuclear antibodies test by immunoflourescence for ITP patients.~6. Bone marrow aspiration (for diagnosis of ITP).~7. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry.
Study: NCT04727606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ure-Na
Description: * Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day)~* Treatment will continue for approximately 1 month.
Study: NCT05402098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic treatment using traditional access
Description: Endodontic treatment will be carried out following complete removal of pulp chamber roof and achieving straight line access

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic treatment using conservative access
Description: Endodontic treatment will be carried out following partial removal of pulp chamber roof, extended only to the extent which helps to locate all the orifices with no efforts will be made to achieve straight line access
Study: NCT06155877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activité Vaccins et Vaccination - LAMAP
Description: Two activities created by the La Main a la Pate foundation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kidivax Chatbot
Description: A chatbot created by our team to answer the most common questions about vaccination, based on a literature review and on focus groups.
Study: NCT06405698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical closure of myelomeningocele defects by perforator-plus flaps
Description: closure of myelomeningocele defect by perforator-plus island flap harvesting leaving skin bridge connecting to the flap and dissection of the perforator vessel
Study: NCT05638841

Intervention type: OTHER
Intervention: After radiofrequency ablation of atrial fibrillation
Description: This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.
Study: NCT04798365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: medical education and distribution of educations materials
Study: NCT04860765

Intervention type: DEVICE
Intervention: SAPIEN 3 THV
Description: SAPIEN 3 THV in the pulmonic position
Study: NCT05393505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Injection
Description: Given if patient has no known allergies at 1 g IV bolus within 1 hour of ED registration, then every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem Injection
Description: Given if patient has no known allergies at 1 g IV bolus within 1 hour of ED registration, then every 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Given if patient is allergic to beta lactam at 500 g IV in 100 mL 0.9% sodium chloride solution, infused over 1 hour started within 1 hour of ED registration, then every 24 hours. If the patient can tolerate oral drugs, 500 mg daily after the first IV dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Given if patient is allergic to beta lactam at 500 g IV in 100 mL 0.9% sodium chloride solution, infused over 1 hour started within 1 hour of ED registration, then every 24 hours. If the patient can tolerate oral drugs, 500 mg daily after the first IV dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: Given if patient has no known allergies at 1.2 g IV bolus within 1 hour of ED registration, then every 8 hours. If the patient can tolerate oral drugs, 1 g twice daily after the first IV bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Any antibiotic for empirical therapy of common infections as recommended by the fifth version of Hospital Authority Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT) guideline, with reference to previous bacterial sensitivity pattern
Study: NCT05318209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Closed-chain Shoulder Girdle Scapular Depression Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Closed-chain Shoulder Girdle Scapular Depression Exercise
Study: NCT06026774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-R01 in combination with standard adjuvant therapy
Description: Personalized mRNA vaccine encoding neoantigen, IH injection
Study: NCT05800145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource information Supplemental Nutrition Assistance Program (SNAP)
Description: Participants randomized to the resource referral arm will receive a tailored list of information about community resources. The list will include information about local emergency food resources (e.g. local food pantries) and government programs to address FI (e.g. SNAP).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: community health worker (CHW)
Description: Participants randomized to the CHW intervention will have an initial baseline visit scheduled at a mutually convenient location.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: medically tailored meals
Description: Participants will receive 10 medically tailored meals delivery to their home weekly for 3 months
Study: NCT06496074

Intervention type: DIAGNOSTIC_TEST
Intervention: Head-up Tilt Test
Description: Two protocols for the head-up tilt test (HUTT) are used in our center and in the collaborating centers: (1) passive or prolonged inclination protocol \[40 minutes\], (2) mixed protocol: passive phase \[first 20 minutes\] plus nitrate-provoked phase \[last 20 minutes\], with the use of 1.25 mg sublingual isosorbide dinitrate. All patients are submitted to 10 minutes of rest in the supine position at zero degree before the tilt phase of the HUTT. During this period, HR and systolic (SBP) and diastolic (DBP) measurements are obtained every 2 minutes. After this phase, the table is tilted at an angle of 70° with measurement of SBP / DBP and HR every minute. Patients older than 60 years are routinely investigated for carotid sinus hypersensitivity by carotid sinus massage during the passive phase of the HUTT. The exam is considered positive according to the criteria defined in guidelines.

Intervention type: DIAGNOSTIC_TEST
Intervention: Head-up Tilt Test
Description: Two protocols for the head-up tilt test (HUTT) are used in our center and in the collaborating centers: (1) passive or prolonged inclination protocol \[40 minutes\], (2) mixed protocol: passive phase \[first 20 minutes\] plus nitrate-provoked phase \[last 20 minutes\], with the use of 1.25 mg sublingual isosorbide dinitrate. All patients are submitted to 10 minutes of rest in the supine position at zero degree before the tilt phase of the HUTT. During this period, HR and systolic (SBP) and diastolic (DBP) measurements are obtained every 2 minutes. After this phase, the table is tilted at an angle of 70° with measurement of SBP / DBP and HR every minute. Patients older than 60 years are routinely investigated for carotid sinus hypersensitivity by carotid sinus massage during the passive phase of the HUTT. The exam is considered positive according to the criteria defined in guidelines.
Study: NCT05492370

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EpiCor
Description: 2 gummies daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 gummies daily
Study: NCT04601038

Intervention type: DRUG
Group type: OTHER
Intervention: CORT108297
Description: 120mg of a selective glucocorticoid receptor antagonist, taken as 2 tablets daily for 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: CORT108297
Description: 120mg of a selective glucocorticoid receptor antagonist, taken as 2 tablets daily for 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo taken as 2 tablets daily for 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo taken as 2 tablets daily for 2 weeks
Study: NCT05123677

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive haemodynamic assessment
Description: Maternal non-invasive haemodynamic assessment: a pressure cuff (similar to the one used to measure blood pressure) is applied to the arm and thigh, and a further neck sensor applied. Information about the function of heart and major blood vessels are recorded

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive haemodynamic assessment
Description: Maternal non-invasive haemodynamic assessment: a pressure cuff (similar to the one used to measure blood pressure) is applied to the arm and thigh, and a further neck sensor applied. Information about the function of heart and major blood vessels are recorded

Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal ophthalmic artery doppler
Description: Maternal ophthalmic artery doppler: an ultrasound probe is applied gently over the eyelid for a few seconds to study the blood flow of the main artery to the eye
Study: NCT02637986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Urex Plus - containing L. rhamnosus GR-1 and L. reuteri RC-14
Description: 2 capsules will be given per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - capsule with no active ingredient
Description: 2 capsules will be given per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - capsule with no active ingredient
Description: 2 capsules will be given per day
Study: NCT05900271

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: 10 Hz repetitive-transcranial-magnetic-stimulation
Study: NCT06438991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjustment of spinal cord stimulation parameters for voluntary motor control
Description: All patients will receive a spinal cord stimulator and undergo adjustment of stimulation parameters for optimal voluntary lower extremity motor control during research visits. Muscle strength will be assessed with the stimulation turned on and off.
Study: NCT06078475

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
Study: NCT06441006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Frequency: daily Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Frequency: daily Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Frequency: daily Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Frequency: daily Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Frequency: daily Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Frequency: daily Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Frequency: daily Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Frequency: daily Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm FQ-S MDR/RR-TB regimen, designed according to latest WHO guidelines
Description: The local SOC regimen consistent with preferred regimen(s) in international guidelines. In most cases this will be 26 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (6BPaLM). Doses and durations of each component may change based on the latest WHO guidelines and the local SOC.
Study: NCT05525910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nirmatrelvir/ ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
Study: NCT05685303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alleviant ALV1 System
Description: Creation of interatrial shunt

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-Control
Description: Cardiac imaging
Study: NCT05030467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REDUCE-BP Intervention
Description: Pre-visit:~Providers in the intervention arm will receive dashboards which will highlight racial/ethnic differences in rates of achieving blood pressure control within their patient panel. The dashboard will also provide individual-level information for patients with poorly controlled blood pressure.~During visit:~Providers will receive clinical decision support within relevant patients' charts that highlight the patient's under-treated blood pressure and potential impacts of social needs.~Providers will have the opportunity to provide enhanced patient education materials, which can be automatically ordered within the clinical decision support.~Post-visit:~Patient-subjects' access to the online patient portal will be streamlined by the inclusion of information about the patient portal in the patients' after-visit summary. Providers will also be able to referral patients automatically to nurse BP visits.
Study: NCT05419232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short Message Service (SMS) + Website Link Strategy
Description: The intervention we are evaluating is the effectiveness of a participant receiving a SMS + Website Link as a vaccine uptake strategy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phone Call with Peer Strategy
Description: The intervention we are evaluating is the effectiveness of a participant having a phone call with a peer as a vaccine uptake strategy
Study: NCT05275673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapanisertib
Description: capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapanisertib
Description: capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapanisertib
Description: capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapanisertib
Description: capsules for oral administration
Study: NCT05250037

Intervention type: PROCEDURE
Intervention: Home spirometry
Description: Undergo spirometry measurements

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo nasal and/or oral swabs, and blood collection

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT06124222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic oral rehabilitation
Description: Prosthetic rehabilitation with fixed and/or removable prosthesis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prosthetic oral rehabilitation
Description: Prosthetic rehabilitation with fixed and/or removable prosthesis.
Study: NCT05631249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib 120Mg Tab
Description: Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up
Study: NCT04375800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: DOR capsules (3.2 to 100 mg); sachets (3.2 to 100 mg); or tablets (100 mg) taken once or twice daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 NRTIs
Description: Participants receive 2 NRTIs per local label by mouth for 96 weeks as background therapy.
Study: NCT05448950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIG Continued Access Study
Description: Small skin incisions will be made for tunneling the graft under the skin in a standard manner. The VIG device is provided pre-loaded within a customized catheter-based delivery system for over-the-wire delivery. The VIG is inserted through an introducer sheath placed in the target vein so that the 'vessel end' of the VIG is deployed within the vein, and the 'graft end' extends out of the vein for connection to the graft. Delivery and deployment will be performed under fluoroscopic guidance. The VIG will be deployed first, connected to the AVG, then the graft and VIG will be flushed and clamped. The arterial anastomosis will then be created using a standard suturing method.
Study: NCT04875520

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening testing strategy
Description: The intervention we are evaluating is the use of weekly screening testing among students and staff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No screening testing strategy
Description: a group of schools will not receive screening testing.
Study: NCT05026723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MTM + ILI
Description: Weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard MTM
Description: Weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian
Study: NCT06311799

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WIC Referral
Description: Clinical team will refer study participants to WIC

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WIC Referral
Description: Clinical team will refer study participants to WIC

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RDN Referral
Description: Clinical team will refer study participants to a RDN

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RDN Referral
Description: Clinical team will refer study participants to a RDN
Study: NCT05592548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cold atmospheric plasma
Description: Cold atmospheric plasma will be generated on the skin surface using an electric device
Study: NCT05889286

Intervention type: DRUG
Intervention: [F-18]MHF
Description: Following intravenous injection of 10 ± 2 mCi (370 ± 74 MBq) \[F-18\]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed. The uptake pattern of \[F-18\]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.

Intervention type: DRUG
Intervention: [F-18]MHF
Description: Following intravenous injection of 10 ± 2 mCi (370 ± 74 MBq) \[F-18\]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed. The uptake pattern of \[F-18\]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.
Study: NCT05462912

Intervention type: DEVICE
Group type: OTHER
Intervention: custom foot orthotic
Description: The goal of this study is to find out whether the use of software generated custom-made orthopedic foot orthoses improves pain in the long term.
Study: NCT05900271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: neuronavigated intermittent theta burst transcranial-magnetic-stimulation
Study: NCT05404958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA)
Description: What is SAIA? It is a 5-step cycle that is repeated every 4-6 weeks for continuous quality improvement, implemented by Kenyan public health workforce and FP clinic staff, and monitored by Mombasa DOH.~Step 1: Understanding the cascade from FP clinic enrollment to HIV testing to linkage to treatment and prevention services.~Step 2: Use process mapping to identify modifiable bottlenecks. Step 3: Define and implement workflow adaptations to eliminate modifiable bottlenecks.~Step 4: Monitor change in performance. Step 5: Repeat the analysis and improvement cycle (steps 1-4).
Study: NCT05993377

Intervention type: OTHER
Intervention: Logistic regression Cross validation Area under the RIC curves Machine learning analysis. .
Description: we will use robust machine learning approaches, such as Random Forest and XGBoost.

Intervention type: OTHER
Intervention: Logistic regression Cross validation Area under the RIC curves Machine learning analysis. .
Description: we will use robust machine learning approaches, such as Random Forest and XGBoost.
Study: NCT05960799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CON - Contiplex C™ (CC)
Description: This is a catheter used for peripherical nerve block that is inserted at the same time that the needle is being introduced. When the target is achieved, the needle is retired.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CTN - Contiplex
Description: This is the traditional catheter used in this centre for peripheric nerve block. In this catheter the needle is introduced first. When the target is achieved the catheter is then introduced throw the needle and after that the needle is retired.
Study: NCT05614505

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to use therapeutic foods
Description: locally produced therapeutic foods

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to use therapeutic foods
Description: locally produced therapeutic foods

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to use therapeutic foods
Description: locally produced therapeutic foods

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to use therapeutic foods
Description: locally produced therapeutic foods

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready to use therapeutic foods
Description: locally produced therapeutic foods